Robert Uzzo, MD, MBA, FACS

Robert Uzzo, MD, FACS

Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Huntingdon Pike
    8 Huntingdon Pike
    Rockledge, PA 19046
    Phone: 888-369-2427

President & CEO, Fox Chase Cancer Center

Executive Vice President for Cancer Services – Temple University Health System

Senior Associate Dean, Clinical Cancer Research – Lewis Katz School of Medicine at Temple University

G. Willing "Wing" Pepper Chair in Cancer Research

Specialties

  • Urology

Areas of Expertise

Adrenal Tumor, Penile Cancer, Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer, Urethral Cancer

Treatment Focus

  • Robotic and laparoscopic urologic oncology
  • Organ preservation (kidney, bladder, testicular and adrenal)
  • Non-surgical management of low risk urinary tumors
  • Complex urological reconstruction

Research Program

Distinctions

Treatment Philosophy

I believe in treating patients as I would my own family. I strive to communicate effectively with patients and family members at all levels. Through extensive discussions with my patients, I develop treatment plans that are both effective and acknowledge that quality of life issues are exceptionally important. I emphasize individually tailored treatments to help patients achieve success and limit treatment-related side effects which can affect quality of life.

I am sensitive to the particular issues regarding surgical treatment of genitourinary cancer, especially the physical and emotional effects on patients and their family. By fostering a doctor-patient relationship based on mutual respect and open dialogue, I encourage patients to become empowered managers of their care... Expand

As a fellowship-trained laparoscopic and robotic urologic oncologist, I am specially trained in nerve-sparing, organ sparing and organ reconstructive surgical techniques for men and women. These strategies are essential for preserving normal functions. For instance, I perform kidney sparing surgery whenever possible to avoid future risks of dialysis. For prostate or testicular surgery, nerve preservation is essential; and when bladder removal is necessary, reconstruction of a new (neobladder) is my preferred approach.

Professionally, I have published more than 300 journal papers in urologic oncology and have lectured extensively regionally, nationally and internationally on the topics of kidney, prostate, bladder, and testicular cancer. I am the principle investigator or co-investigator on multiple national and regional clinical trials in urologic oncology. Because of my research and extensive membership in professional organizations, I am among the first to know what is new in urologic cancer treatment. Philadelphia magazine has chosen me for its "Top Doctors" list every year since 2002. Collapse

Bio

As President & CEO, Fox Chase Cancer Center, Robert Uzzo is responsible for leading the overall clinical operations of Fox Chase.

In addition to these roles, Uzzo is the G. Willing “Wing” Pepper Chair in Cancer Research and also serves as the organization’s President of the Medical Group. He also serves as the founding Executive Director of the nation’s second largest urologic quality collaborative, the Pennsylvania Urologic Regional Collaborative.

... Expand

Educational Background

  • Fellow, Urologic Oncology, Cleveland Clinic Foundation
  • Fellow, Renal Transplantation and Renovascular Surgery, Cleveland Clinic Foundation
  • Chief Resident, Urology, New York Hospital-Cornell University Medical Center, New York, NY
  • Senior Resident, Urology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • MD, Cornell Medical College, New York, NY, 1991
  • BS/BA, Union College, Schenectady, NY, 1987, Valedictorian

Certifications

  • American Board of Urology

Memberships

  • The American Urological Association
  • Member, American Association of Genitourinary Surgeons, AAGUS
  • Society of Urologic Oncology, Board of Directors
  • Society of Urologic Oncology, Clinical Trials Consortium, President 
  • Society of Urologic Oncology, Clinical Trials Consortium, Renal Program Chairman  
  • Board of Directors, SUO Clinical Trials Consortia, member-at-large  
  • Fox Chase Cancer Center Society of Scholars  
  • Kidney Cancer Association Medical Advisory Board  
  • Fellow American College of Surgeons (F.A.C.S.)  
  • Society of Urologic Oncology  
  • Pennsylvania Medical Society
  • Philadelphia County Medical Society  
  • The MidAtlantic Section of the American Urological Association
  • Eastern Cooperative Oncology Group  
  • Radiation Therapy Oncology Group
  • American College of Surgeons Oncology Group - Vice Chairman, GU Organ Committee   2002-2006 
  • American Society of Transplant Surgeons 
  • Urologic Society of Transplant and Vascular Surgeons
  • Society for Basic Urologic Research  
  • American Association for Cancer Research

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2002-24
  • Best Doctors in America®, 2013-16, 2019-2020, Urology
  • America’s Top Doctors®, 2008-17
  • AUA Residents National Committee Teaching Award
  • Consumer’s Research Council of America –America’s Top Physicians 
Link to /sites/default/files/styles/patient_story/public/images/patient-stories/Faus-Photo2_0.jpg?h=97a6072e&itok=KAG_afgM

Norm Faus III

  • Kidney Cancer

My name is Norm Faus III. I live in Lititz, Pennsylvania, which is about 80 miles west of Philadelphia. My wife and I have been married for 53 years. We have two grown children and several grandchildren. That makes me an old man of 73.

Generally, I’ve been very healthy over the years. The only thing I did develop, about 20 years ago, is peripheral neuropathy. It was what the doctors call idiopathic, meaning I didn’t have diabetes or cancer or anything that would have caused it to develop. Otherwise, I haven’t had any serious health issues.

VIEW PATIENT STORY

Research Interests

  • Clinical and translational questions involving renal cell carcinoma including decision making models in the management of renal cancers and processes/quality of care in urologic malignancies
  • Analyses of outcomes involving excision, ablation, and active surveillance for localized kidney cancer and techniques/outcomes of surgery in locally advanced and metastatic RCC
  • Actively develop and accrue to multiple industry sponsored national and international urological oncology trials as well as investigator initiated trials.
  • Translational interests include biomarker development in kidney cancer and the role of zinc dyshomeostasis in prostate cancer
p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 14.0px Calibri; -webkit-text-stroke: #000000} span.s1 {font-kerning: none}

Selected Publications

Chapters and Publications from over 400:

Correa A.F., Jegede O.A., Haas N.B., Flaherty K.T., Pins M.R., Adeniran A., Messing E.M., Manola J., Wood C.G., Kane C.J., Jewett M.A.S., Dutcher J.P., DiPaola R.S., Carducci M.A., Uzzo R.G., Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol. 80(1): 20-31, 2021. PMC8627688. https://www.ncbi.nlm.nih.gov/pubmed/33707112.

Smith S.M., Wachter K., Burris H.A., 3rd, Schilsky R.L., George D.J., Peterson D.E., Johnson M.L., Markham M.J., Mileham K.F., Beg M.S., Bendell J.C., Dreicer R., Keedy V.L., Kimple R.J., Knoll M.A., LoConte N., MacKay H., Meisel J.L., Moynihan T.J., Mulrooney D.A., Mulvey T.M., Odenike O., Pennell N.A., Reeder-Hayes K., Smith C., Sullivan R.J., Uzzo R., Clinical cancer advances 2021: Asco's report on progress against cancer. J Clin Oncol. 39(10): 1165-1184, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33527845.

Campbell S.C., Novick A.C., Belldegrun A., Blute M.L., Chow G.K., Derweesh I.H., Faraday M.M., Kaouk J.H., Leveillee R.J., Matin S.F., Russo P., Uzzo R.G., Guideline for Management of the Clinical T1 Renal Mass, 2009, Journal of Urology, 182, 4 SUPPL., 1271, 1279 PubMed

Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018. 

Uzzo R.G., Novick A.C., Nephron sparing surgery for renal tumors: Indications, techniques and outcomes, 2001, Journal of Urology, 166, 1, 6, 18 PubMed

Kutikov A, Uzzo RG. The RENAL Nephrometry Score: A comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol, 182(3):844-53, 2009. (cited 401 times) PubMed

Chawla S.N., Crispen P.L., Hanlon A.L., Greenberg R.E., Chen D.Y.T., Uzzo R.G., The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature, 2006, Journal of Urology, 175, 2, 425, 431 PubMed

Kunkle D.A., Egleston B.L., Uzzo R.G., Excise, Ablate or Observe: The Small Renal Mass Dilemma-A Meta-Analysis and Review, 2008, Journal of Urology, 179, 4, 1227, 1234 PubMed

Kunkle D.A., Uzzo R.G., Cryoablation or radiofrequency ablation of the small renal mass: A meta-analysis, 2008, Cancer, 113, 10, 2671, 2680 PubMed

Uzzo R.G., Wei J.T., Waldbaum R.S., Perlmutter A.P., Byrne J.C., Vaughan Jr. D., The influence of prostate size on cancer detection, 1995, Urology, 46, 6, 831, 836 PubMed

... Expand

Additional Publications

My NCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
Resize Text

Related Articles

00 / 00